Phase I Study of Chemoprevention With Green Tea Polyphenon E (PPE) and the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) in Patients With Premalignant Lesions of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2016
At a glance
- Drugs Erlotinib (Primary) ; Polyphenon E (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 22 Dec 2016 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 22 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 13 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.